Cargando…
VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma
BACKGROUND: Vascular endothelial growth factor (VEGF) isoforms, particularly the diffusible VEGF-121, could play a major role in the response of recurrent glioblastoma (GB) to anti-angiogenetic treatment with bevacizumab. We hypothesized that circulating VEGF-121 may reduce the amount of bevacizumab...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5946426/ https://www.ncbi.nlm.nih.gov/pubmed/29747600 http://dx.doi.org/10.1186/s12885-018-4442-2 |
_version_ | 1783322194725568512 |
---|---|
author | Martini, Maurizio de Pascalis, Ivana D’Alessandris, Quintino Giorgio Fiorentino, Vincenzo Pierconti, Francesco Marei, Hany El-Sayed Ricci-Vitiani, Lucia Pallini, Roberto Larocca, Luigi Maria |
author_facet | Martini, Maurizio de Pascalis, Ivana D’Alessandris, Quintino Giorgio Fiorentino, Vincenzo Pierconti, Francesco Marei, Hany El-Sayed Ricci-Vitiani, Lucia Pallini, Roberto Larocca, Luigi Maria |
author_sort | Martini, Maurizio |
collection | PubMed |
description | BACKGROUND: Vascular endothelial growth factor (VEGF) isoforms, particularly the diffusible VEGF-121, could play a major role in the response of recurrent glioblastoma (GB) to anti-angiogenetic treatment with bevacizumab. We hypothesized that circulating VEGF-121 may reduce the amount of bevacizumab available to target the heavier isoforms of VEGF, which are the most clinically relevant. METHODS: We assessed the plasma level of VEGF-121 in a brain xenograft model, in human healthy controls, and in patients suffering from recurrent GB before and after bevacizumab treatment. Data were matched with patients’ clinical outcome. RESULTS: In athymic rats with U87MG brain xenografts, the level of plasma VEGF-121 relates with tumor volume and it significantly decreases after iv infusion of bevacizumab. Patients with recurrent GB show higher plasma VEGF-121 than healthy controls (p = 0.0002) and treatment with bevacizumab remarkably reduced the expression of VEGF-121 in plasma of these patients (p = 0.0002). Higher plasma level of VEGF-121 was significantly associated to worse PFS and OS (p = 0.0295 and p = 0.0246, respectively). CONCLUSIONS: Quantitative analysis of VEGF-121 isoform in the plasma of patients with recurrent GB could be a promising predictor of response to anti-angiogenetic treatment. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-018-4442-2) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5946426 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-59464262018-05-14 VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma Martini, Maurizio de Pascalis, Ivana D’Alessandris, Quintino Giorgio Fiorentino, Vincenzo Pierconti, Francesco Marei, Hany El-Sayed Ricci-Vitiani, Lucia Pallini, Roberto Larocca, Luigi Maria BMC Cancer Research Article BACKGROUND: Vascular endothelial growth factor (VEGF) isoforms, particularly the diffusible VEGF-121, could play a major role in the response of recurrent glioblastoma (GB) to anti-angiogenetic treatment with bevacizumab. We hypothesized that circulating VEGF-121 may reduce the amount of bevacizumab available to target the heavier isoforms of VEGF, which are the most clinically relevant. METHODS: We assessed the plasma level of VEGF-121 in a brain xenograft model, in human healthy controls, and in patients suffering from recurrent GB before and after bevacizumab treatment. Data were matched with patients’ clinical outcome. RESULTS: In athymic rats with U87MG brain xenografts, the level of plasma VEGF-121 relates with tumor volume and it significantly decreases after iv infusion of bevacizumab. Patients with recurrent GB show higher plasma VEGF-121 than healthy controls (p = 0.0002) and treatment with bevacizumab remarkably reduced the expression of VEGF-121 in plasma of these patients (p = 0.0002). Higher plasma level of VEGF-121 was significantly associated to worse PFS and OS (p = 0.0295 and p = 0.0246, respectively). CONCLUSIONS: Quantitative analysis of VEGF-121 isoform in the plasma of patients with recurrent GB could be a promising predictor of response to anti-angiogenetic treatment. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-018-4442-2) contains supplementary material, which is available to authorized users. BioMed Central 2018-05-10 /pmc/articles/PMC5946426/ /pubmed/29747600 http://dx.doi.org/10.1186/s12885-018-4442-2 Text en © The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Martini, Maurizio de Pascalis, Ivana D’Alessandris, Quintino Giorgio Fiorentino, Vincenzo Pierconti, Francesco Marei, Hany El-Sayed Ricci-Vitiani, Lucia Pallini, Roberto Larocca, Luigi Maria VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma |
title | VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma |
title_full | VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma |
title_fullStr | VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma |
title_full_unstemmed | VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma |
title_short | VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma |
title_sort | vegf-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5946426/ https://www.ncbi.nlm.nih.gov/pubmed/29747600 http://dx.doi.org/10.1186/s12885-018-4442-2 |
work_keys_str_mv | AT martinimaurizio vegf121plasmalevelasbiomarkerforresponsetoantiangiogenetictherapyinrecurrentglioblastoma AT depascalisivana vegf121plasmalevelasbiomarkerforresponsetoantiangiogenetictherapyinrecurrentglioblastoma AT dalessandrisquintinogiorgio vegf121plasmalevelasbiomarkerforresponsetoantiangiogenetictherapyinrecurrentglioblastoma AT fiorentinovincenzo vegf121plasmalevelasbiomarkerforresponsetoantiangiogenetictherapyinrecurrentglioblastoma AT piercontifrancesco vegf121plasmalevelasbiomarkerforresponsetoantiangiogenetictherapyinrecurrentglioblastoma AT mareihanyelsayed vegf121plasmalevelasbiomarkerforresponsetoantiangiogenetictherapyinrecurrentglioblastoma AT riccivitianilucia vegf121plasmalevelasbiomarkerforresponsetoantiangiogenetictherapyinrecurrentglioblastoma AT palliniroberto vegf121plasmalevelasbiomarkerforresponsetoantiangiogenetictherapyinrecurrentglioblastoma AT laroccaluigimaria vegf121plasmalevelasbiomarkerforresponsetoantiangiogenetictherapyinrecurrentglioblastoma |